Immunization of pregnant women against pertussis: The effect of timing on antibody avidity

Vaccine

Volumn 33, Issue 16, 2015, Pages 1948-1952

  Abu Raya, Bahaa ^a,b   Bamberger, Ellen ^a,b   Almog, Meital ^a,b   Peri, Regina ^a   Srugo, Isaac ^a,b   Kessel, Aharon ^a,b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Immunoglobulin G; Pertussis; Pertussis toxin; Relative avidity index; Tetanus diphtheria acellular pertussis maternal immunization

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G; PERTUSSIS TOXIN; BACTERIUM ANTIBODY;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNIZATION; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; NEWBORN; PERTUSSIS; PREGNANT WOMAN; PRIORITY JOURNAL; RELATIVE AVIDITY INDEX; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD; ANTIBODY AFFINITY; BORDETELLA PERTUSSIS; IMMUNOLOGY; MALE; MIDDLE AGED; MORBIDITY; PREGNANCY; YOUNG ADULT;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; GESTATIONAL AGE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INFANT, NEWBORN; MALE; MIDDLE AGED; MORBIDITY; PREGNANCY; YOUNG ADULT;

EID: 84933178433     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.059     Document Type: Article

References (39)

1. Chiappini E., Stival A., Galli L., de Martino M. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013, 13:151. 10.1186/1471-2334-13-151.
2. Winter K., Harriman K., Zipprich J., et al. California pertussis epidemic, 2010. J Pediatr 2012, 1:1091-1096.
3. Cherry J.D. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N Engl J Med 2012, 367:785-787.
4. Centers for Disease Control and Prevention (CDC) Pertussis epidemic 2012, 61:517-522. MMWR, Washington, DC.
5. Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Surveillance and Reporting. Available at: . Accessed March 3, 2015. http://www.cdc.gov/pertussis/surv-reporting.html.
6. CDC Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60:1424-1426.
7. Centers for Disease Control and Prevention. CDC features. Help Protect Babies from Whooping Cough. Available at: . Accessed March 3, 2015. http://www.cdc.gov/features/pertussis/.
8. Israel Ministry of Health, Division of Epidemiology. Letter number 51050612, date: October 22; 2012.
9. Israel Ministry of Health, Division of Epidemiology. Letter number 4112143, date: July 18; 2013.
10. Goodnow C.C., Vinuesa C.G., Randall K.L., Mackay F., Brink R. Control systems and decision making for antibody production. Nat Immunol 2010, 11:681-688.
11. Abu Raya B., Srugo I., Kessel A., et al. The induction of breast milk pertussis specific antibodies following gestational tetanus-diphtheria-acellular pertussis vaccination. Vaccine 2014, 32(43):5632-5637.
12. Abu Raya B., Srugo I., Kessel A., et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels-a prospective study. Vaccine 2014, 32(44):5787-5793.
13. Goldblatt D., Pinto Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998, 177(4):1112-1115.
14. Hofmann J., Lierbt U.G. Significance of avidity and immunoblot analysis for rubella IgM-positive serum samples in pregnant women. J Virol Methods 2005, 130:66-71.
15. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996, 272:54-60.
16. Barkoff A.M., Gröndahl-Yli-Hannukselaa K., Vuononvirtaa J., Mertsolab J., Kallonen T., He Q. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine 2012, 30(48):6897-6902.
17. Prelog M., Almanzar G., Rieber N., Ottensmeier B., Zlamy M., Liese J. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination. Vaccine 2013, 31(2):387-393.
18. Baughman A.L., Bisgard K.M., Edwards K.M., et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 2004, 11(6):1045-1053.
19. Almanzar G., Ottensmeier B., Liese J., Prelog M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J Immunol Methods 2013, 387(1-2):36-42.
20. Englund J.A. The influence of maternal immunization on infant immune responses. J Comp Pathol 2007, 137(Suppl. 1):S16-S19.
21. Mooi F.R., de Greeff S.C. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007, 7(9):614-624.
22. Liesenfeld O., Montoya J.G., Kinney S., Press C., Remington J.S. Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis 2001, 183(8):1248-1253.
23. Dorner T., Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 2007, 27(3):384-392.
24. Berek C., Berger A., Apel M. Maturation of the immune response in germinal centers. Cell 1991, 67:1121-1129.
25. Kepler T.B., Perelson A.S. Somatic hypermutation in B cells: an optimal control treatment. J Theor Biol 1993, 164(1):37-64.
26. Klein U., Kuppers R., Rajewsky K. Variable region gene analysis of B cell subsets derived from a 4-year-old child: somatically mutated memory B cells accumulate in the peripheral blood already at young age. J Exp Med 1994, 180:1383-1393.
27. De Guow D., Diavatopoulos D.A., Bootsma H.J., Hermans P.W., Mooi F.R. Pertussis A matter of immune modulation. FEMS Microbiol Rev 2011, 35(3):441-474.
28. Carbonetti N.H. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol 2010, 5(3):455-469.
29. Munoz J.J., Arai H., Bergman R.K., Sadowski P.L. Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun 1981, 33(3):820-826.
30. Morse S.I., Morse J.H. Isolation and properties of the leukocytosis- and lymphocytosis-promoting factor of Bordetella pertussis. J Exp Med 1976, 143:1483-1492.
31. Melvin J.A., Scheller E.V., Miller J.F., Cotter P.A. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol 2014, 12(4):274-288.
32. Hewlett E.L., Burns D.L., Cotter P.A., et al. Pertussis pathogenesis-what we know and what we don't know. J Infect Dis 2014, 209(7):982-985.
33. Mikelova L.K., Halperin S.A., Scheifele D., et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003, 143:576-581.
34. Paddock C.D., Sanden G.N., Cherry J.D., et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008, 47(3):328-338.
35. Kneitz R.H., Schubert J., Tollmann F., et al. A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid. BMC Infect Dis 2004, 4:1-11.
36. Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992, 267:1489-1494.
37. Denoël P.A., Goldblatt D., de Vleeschauwer I., Jacquet J.M., Pichichero M.E., Poolman J.T. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007, 14(10):1362-1369.
38. Anttila M., Eskola J., Ahman H., Käyhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998, 177(6):1614-1621.
39. Safaeian M., Kemp T.J., Pan D.Y., et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 2013, 9(7):1399-1406.